Through its acquisition of G-CON, Sum of equity enters rapid growth biopharmaceutical manufacturing market, including manufacture of cell and gene therapies.
STOCKHOLM, July 20, 2021 / PRNewswire / – Summa Equity Fund II (âSummaâ) has acquired a controlling interest in G-CON, a leading US manufacturer of prefabricated clean rooms used for manufacturing in the pharmaceutical industry. G-CON designs, builds and installs turnkey GMP (Current Good Manufacturing Practices) suites called PODs, for a global biopharmaceutical customer base focused on biologics, pharmaceuticals, CDMOs (contract development and manufacturing) and manufacturing cell and gene therapy.
Founded in 2009 in University Station, Texas, G-CON has developed a unique prefabricated cleanroom solution, which differs from traditional cleanroom facility structures due to the ease of scalability, mobility, and the ability to reuse PODs once the process is completed. production reaches the end of its life cycle. The company has experienced strong growth and has sold more than 300 clean rooms since its inception.
As the biopharmaceutical market evolves, emerging modalities, such as cell and gene therapy, and the need to rapidly evolve manufacturing requirements, have resulted in a pressing demand for off-site built solutions that can be manufactured, installed and scaled quickly. The COVID-19 pandemic has underscored the need for uninterrupted off-site construction of cleanroom infrastructure.
G-CON has become a market leader in meeting this demand, with high-quality, scalable and flexible manufacturing solutions delivered on fast and reliable delivery times. Its value proposition is particularly relevant to the growing and highly complex biologics and personalized medicine market, which has unique manufacturing requirements.
By addressing and disrupting the boundaries of conventional manufacturing processes that many biopharmaceutical manufacturers face, G-CON aligns itself with Summa’s focus on solving global challenges and its theme of changing demographics, as well as on the Sustainable Development Goals (SDGs) n Â° 3 of the UN: “Ensure good health of life and promote the well-being of all at all ages”, and # 9: “Industry, innovation and infrastructure”.
Summa supports the company on its journey to become one of the world’s leading providers of turnkey bioprocessing solutions by expanding the range of products and services and establishing a local presence outside of the United States.
“We are proud to partner with G-CON for the next exciting chapter of its growth trajectory â, says Marika VitiÃ¤, director at Summa Equity. “We are confident that G-CON has the potential to dramatically speed up bioprocess production times, help biopharmaceutical manufacturers enter the market earlier and fully meet their post-launch capacity needs. It is a vitally important part of the healthcare value chain, ensuring that more of society has access to the right healthcare when it needs it. ”
“We are extremely excited to be partnering with Summa Equity as their vision and activities support our goal of helping more patients get affordable medication quickly. With Summa’s support, we will expand our capabilities, services and product offerings, to transform manufacturing capability in the biopharmaceutical market. We look forward to working with the team to further accelerate the global adoption of our unique bioprocessing solutions â, mentionned Maik jornitz, CEO of G-CON.
The transaction closes on July 15, 2021. Guillaume Blair acted as exclusive financial advisor, Ropes & Gray as legal advisor, PwC as FDD and tax advisor, McKinsey & Company as business due diligence advisor and Frank Partners as ESG advisor to Summa Equity for the transaction. Jefferies LLC served as exclusive financial advisor and Vinson & Elkins LLP as legal advisor to G-CON.
About Summa Equity
Summa invests in companies that solve global challenges and create positive environmental, social and governance (ESG) outcomes for society.
Summa’s goal is to co-create a win-win for investors, portfolio companies and society by aligning its vision and results with sustainability goals, ensuring a net positive impact on ESG challenges and the potential for long-term sustainable outperformance. .
Investments are focused on industries and businesses within three sustainability megatrends: resource efficiency, demographics, and technology companies. On these themes, Summa’s portfolio companies support a world in transition and show that businesses can be part of the solution. Summa has more than 1.4 billion euros in assets under management.
About G-CON Manufacturing, Inc.
G-CON Manufacturing designs, builds and installs G-CON PODÂ® prefabricated cleanrooms. G-CON’s POD portfolio provides cleanrooms in a number of sizes for a variety of uses, from lab environments to personalized medicine and production process platforms. G-CON PODÂ® cleanroom units outperform traditional cleanroom structures in terms of scalability, mobility and the ability to reuse PODs once the production process reaches the end of its lifecycle. For more information, please visit the G-CON website at https://www.gconbio.com. G-CON manufacturingâ¦ BUILDING FOR LIFE â¢
Logo – https://mma.prnewswire.com/media/1438062/G_CON_Manufacturing_Inc_Logo.jpg